Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vernalis Raises $100 million To Support Push Into U.S. Rx Cough/Cold Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Vernalis reveals new strategy to market long-acting prescription cough/cold preparations in the US, supported by Tris Pharma's technology and a $104 million fundraising

You may also be interested in...



Vernalis Seeks Buyers, CEO To Step Down, As US Commercial Strategy Disappoints

Disappointing sales growth of its prescription extended-release cough-and-cold product has led Vernalis to decide to close down its US commercial operations, and to seek a buyer for the whole company.

 

Vernalis Considers US Deals As Prescription Cough/Cold Strategy Delivers

Vernalis launches its first long-acting liquid cough and cold product, Tuzistra XR, in the US as part of a revised business focus on generating sustainable revenues from low development risk, late-stage products.

Financings Of The Fortnight: Big FOPO For Troubled Alnylam, Plus First European IPO Of 2012 For Adocia

Plus news on recent financing by Satori, Ceptaris, Vernalis and Exelixis

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073749

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel